Ganaxolone: a novel positive allosteric modulator of the GABAA receptor complex for the treatment of epilepsy
- 1 October 1999
- journal article
- Published by Informa Healthcare in Expert Opinion on Investigational Drugs
- Vol. 8 (10) , 1663-1671
- https://doi.org/10.1517/13543784.8.10.1663
Abstract
Ganaxolone is a member of a novel class of neuroactive steroids which modulates the GABAA receptor complex (GRC) via an unique recognition site, distinct from those of benzodiazepines and barbiturates. Preclinical data from an array of chemically- and electrically-induced seizure models demonstrate that ganaxolone possesses broad spectrum anticonvulsant activity with potential clinical utility in both generalised and partial seizures, as well as cocaine-induced seizures. Clinical data to date support a favourable safety profile with somnolence, an extension of GABAergic activity, being the most frequently reported adverse event at higher doses. Target indications include infantile spasms and complex partial seizures. Open-label data in paediatric patients with intractable epilepsy suggest that ganaxolone may be effective in treating infantile spasms. A controlled trial utilising an in-patient, monotherapy design demonstrated that ganaxolone effectively decreases complex partial seizure activity compared t...Keywords
This publication has 13 references indexed in Scilit:
- Patients with Refractory SeizuresNew England Journal of Medicine, 1999
- OxcarbazepineNeurology, 1999
- Three Patterns of Catamenial EpilepsyEpilepsia, 1997
- Gabapentin monotherapy: I. An 8-day, double-blind, dose controlled, multicenter study in hospitalized patients with refractory complex partial or secondarily generalized seizuresNeurology, 1997
- Diagnosis and Treatment of Epilepsy in Children and AdolescentsDrugs, 1996
- Felbamate Monotherapy: Implications for Antiepileptic Drug DevelopmentEpilepsia, 1995
- Progesterone therapy in women with complex partial and secondary generalized seizuresNeurology, 1995
- LamotrigineThe Lancet, 1992
- Epidemiology, classification, natural history, and genetics of epilepsyThe Lancet, 1990
- Anticonvulsant profile of the progesterone metabolite 5α-pregnan-3α-ol-20-oneEuropean Journal of Pharmacology, 1989